The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for amifampridine (ORSPEC Pharma Pty Ltd)
Active ingredients
amifampridine
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
RUZURGI is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above.
Therapeutic area
Neurology